标题
An evaluation of lumateperone tosylate for the treatment of schizophrenia
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-7
出版商
Informa UK Limited
发表日期
2019-12-02
DOI
10.1080/14656566.2019.1695778
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 30 Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study
- (2019) Kimberly Vanover et al. CNS SPECTRUMS
- S117. FAVORABLE LONG-TERM SAFETY PROFILE OF LUMATEPERONE IITI-007): RESULTS FROM A 12 MONTH OPEN LABEL SAFETY STUDY FOR LUMATEPERONE IN PATIENTS WITH STABLE SYMPTOMS OF SCHIZOPHRENIA
- (2019) Kimberly Vanover et al. SCHIZOPHRENIA BULLETIN
- Upcoming market catalysts in Q3 2019
- (2019) Brandon Leavins NATURE REVIEWS DRUG DISCOVERY
- S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY
- (2018) Kimberly Vanover et al. SCHIZOPHRENIA BULLETIN
- Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
- (2018) Kimberly E. Vanover et al. NEUROPSYCHOPHARMACOLOGY
- Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
- (2017) Dejan B. Budimirovic et al. Journal of Neurodevelopmental Disorders
- ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
- (2016) Jeffrey A. Lieberman et al. BIOLOGICAL PSYCHIATRY
- Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?
- (2016) Leslie Citrome CNS SPECTRUMS
- ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
- (2016) Robert E. Davis et al. Expert Review of Neurotherapeutics
- Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression
- (2016) Anthony A. Grace NATURE REVIEWS NEUROSCIENCE
- ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
- (2016) Robert E. Davis et al. Expert Review of Neurotherapeutics
- ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers
- (2015) Robert E. Davis et al. PSYCHOPHARMACOLOGY
- Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders
- (2014) Peng Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
- (2014) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- Poster #S78 THE NOVEL PHARMACOLOGY OF ITI-007 IS ENHANCED AND EXTENDED BY ITS METABOLIC BACK CONVERSION FROM IC200131
- (2014) Robert E. Davis et al. SCHIZOPHRENIA RESEARCH
- From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
- (2010) C.U. Correll EUROPEAN PSYCHIATRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started